Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Growth Outlook and Analyst Views Biocon's vision, as articulated by Tambe, focuses on building a trusted brand through "high-end science and innovation." The company's pipeline is strong, with 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and bone health
An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide
For more information about thyroid cancer, visit:
Loghin, C
US$ 25.13
US$ 29.51
US$ 20.23
US$ 28.80
